What to Know about the Experimental GLP-1 Drug CagriSema
3 min read THESE DAYS, WHEN it comes to weight loss drugs, you’ve got a veritable buffet of…
Should you take GLP-1 drugs for longevity?
This is, indeed, part of a wider trend of mutual support at the fringes of pharmacology, with similar…
FDA sends letter to Novo Nordisk over potential GLP-1 side effects
The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
FDA sends letter to Novo Nordisk over potential GLP-1 side effects
The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
Has anyone died from taking GLP-1 weight-loss drugs? – Baltimore Sun
Has anyone died from taking GLP-1 weight-loss drugs? Baltimore SunPAHO calls for strengthened pharmacovigilance following reports of misuse of…
Table 2.0: Restaurants absorb ‘Ozempic effect’ for weight-loss drug consumers
New Delhi:Dozens of Indian restaurants and cafe chains are fast-tracking Size O menus — the O standing for…
Dr Reddy’s says Wegovy copycat to be priced competitively, with 50-60pc discounts feasible
HYDERABAD, Feb 18 — Indian drugmaker Dr Reddy’s Laboratories hopes to launch a generic version of Novo Nordisk’s…
New drug CagriSema leads to 14% weight loss in trial
Share on PinterestNew combo drug from Novo Nordisk leads to more weight loss than semaglutide alone, according to…
What is 'natural Ozempic' – and how good is the science? – The i Paper
What is ‘natural Ozempic’ – and how good is the science? The i PaperWhat is ‘oatzempic’? Does it actually…
New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways
Summary: Oral pills add flexibility; insurance coverage still varies widely, and compounded options remain unapproved. What “Best Semaglutide”…
Eli Lilly Drug Retatrutide Clinical Trial Results
Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become…
Dulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event risk
1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in…